These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36588396)

  • 41. A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse.
    Bhutani M; Foureau DM; Robinson M; Guo F; Fesenkova K; Atrash S; Paul B; Varga C; Friend R; Pineda-Roman M; Rigby K; Symanowski JT; Norek S; Tucker MR; Druhan LJ; Voorhees PM; Usmani SZ
    Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):535-544.e1. PubMed ID: 37127471
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
    Durie BGM; Hoering A; Sexton R; Abidi MH; Epstein J; Rajkumar SV; Dispenzieri A; Kahanic SP; Thakuri MC; Reu FJ; Reynolds CM; Orlowski RZ; Barlogie B
    Blood Cancer J; 2020 May; 10(5):53. PubMed ID: 32393732
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma.
    Forsberg PA; Rossi AC; Boyer A; Pearse RN; Pekle KA; Jayabalan D; Lakritz S; Flicker K; Ribadeneyra D; Liotta B; Ely S; Boussi L; Allan JN; Coleman M; Niesvizky R; Mark TM
    Am J Hematol; 2021 Dec; 96(12):1554-1562. PubMed ID: 34424561
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies.
    Landgren O; Kazandjian D; Roussel M; Jasielec J; Dytfeld D; Anderson A; Kervin TA; Iskander K; McFadden I; Jakubowiak AJ
    Leuk Lymphoma; 2022 Oct; 63(10):2413-2421. PubMed ID: 35549810
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.
    Dolph M; Tremblay G; Leong H
    Pharmacoeconomics; 2021 Nov; 39(11):1309-1325. PubMed ID: 34368938
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study.
    Gordan LN; Tan CR; Vescio R; Ye JC; Schinke C; Medhekar R; Fu AZ; Lafeuille MH; Thompson-Leduc P; Khare V; Reitan J; Milkovich G; Kaila S; Davies F; Usmani SZ
    Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):55-63. PubMed ID: 37838502
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study.
    Lee JY; Park SS; Jeon YW; Shin SH; Yahng SA; Min CK;
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11907-11918. PubMed ID: 37418057
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan.
    Suzuki K; Ri M; Chou T; Sugiura I; Takezako N; Sunami K; Ishida T; Izumi T; Ozaki S; Shumiya Y; Ota K; Iida S
    Cancer Sci; 2017 Mar; 108(3):461-468. PubMed ID: 28092421
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
    Avet-Loiseau H; Fonseca R; Siegel D; Dimopoulos MA; Špička I; Masszi T; Hájek R; Rosiñol L; Goranova-Marinova V; Mihaylov G; Maisnar V; Mateos MV; Wang M; Niesvizky R; Oriol A; Jakubowiak A; Minarik J; Palumbo A; Bensinger W; Kukreti V; Ben-Yehuda D; Stewart AK; Obreja M; Moreau P
    Blood; 2016 Sep; 128(9):1174-80. PubMed ID: 27439911
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
    Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
    Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of newly diagnosed myeloma: Bortezomib-based triplet.
    Rajan AM; Rajkumar SV
    Semin Oncol; 2016 Dec; 43(6):700-702. PubMed ID: 28061990
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
    Minarik J; Pika T; Radocha J; Jungova A; Straub J; Jelinek T; Pour L; Pavlicek P; Mistrik M; Brozova L; Krhovska P; Machalkova K; Jindra P; Spicka I; Plonkova H; Stork M; Bacovsky J; Capkova L; Sykora M; Kessler P; Stejskal L; Heindorfer A; Ullrychova J; Skacel T; Maisnar V; Hajek R
    BMC Cancer; 2021 Jan; 21(1):73. PubMed ID: 33451293
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study.
    Tan TD; Hong YC; Li SS; Yu JT; Sung YC; Wang PN; Teng CJ
    Chin J Physiol; 2020; 63(5):211-217. PubMed ID: 33109787
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
    Montefusco V; Corso A; Galli M; Ardoino I; Pezzatti S; Carniti C; Patriarca F; Gherlinzoni F; Zambello R; Sammassimo S; Marcatti M; Nozza A; Crippa C; Cafro AM; Baldini L; Corradini P
    Br J Haematol; 2020 Mar; 188(6):907-917. PubMed ID: 31898319
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
    Morabito F; Zamagni E; Conticello C; Pavone V; Palmieri S; Bringhen S; Galli M; Mangiacavalli S; Derudas D; Rossi E; Ria R; Catalano L; Tacchetti P; Mele G; Donatella Vincelli I; Antonia Martino E; Vigna E; Botta C; Bruzzese A; Mele A; Pantani L; Rocchi S; Garibaldi B; Cascavilla N; Ballanti S; Tripepi G; Frigeri F; Pia Falcone A; Cangialosi C; Reddiconto G; Farina G; Barone M; Rizzello I; Musto P; De Stefano V; Musso M; Teresa Petrucci M; Offidani M; Neri A; Di Renzo N; Di Raimondo F; Boccadoro M; Cavo M; Gentile M
    Eur J Haematol; 2022 Mar; 108(3):178-189. PubMed ID: 34716957
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
    Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Allotey D; Shafeek S; Jenner MW; Cook G; Russell NH; Kaiser MF; Drayson MT; Owen RG; Gregory WM; Morgan GJ; Clinical Studies Group UNHO
    Haematologica; 2021 Jul; 106(7):1957-1967. PubMed ID: 32499244
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.
    Mangiacavalli S; Cartia CS; Galli M; Pezzatti S; Belotti A; Fazio F; Mina R; Marcatti M; Cafro A; Zambello R; Paris L; Barilà G; Olivares C; Pompa A; Mazza R; Farina F; Soldarini M; Benvenuti P; Pagani G; Palumbo M; Masoni V; Ferretti VV; Klersy C; Arcaini L; Petrucci MT
    Haematologica; 2023 Mar; 108(3):833-842. PubMed ID: 36200419
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcomes of lenalidomide- or bortezomib-based regimens in older patients with plasma cell myeloma.
    Barth P; Giri S; Reagan JL; Olszewski AJ
    Am J Hematol; 2021 Jan; 96(1):14-22. PubMed ID: 32918301
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
    Costa LJ; Chhabra S; Medvedova E; Dholaria BR; Schmidt TM; Godby KN; Silbermann R; Dhakal B; Bal S; Giri S; D'Souza A; Hall AC; Hardwick P; Omel J; Cornell RF; Hari P; Callander NS
    Lancet Haematol; 2023 Nov; 10(11):e890-e901. PubMed ID: 37776872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.